Could this be the secret to Pfizer's rebound strategy?
It could prove to be a case of better later than never for the healthcare giant.
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.
Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and entertainment news.
Albert Bourla, Pfizer Chairman & CEO, addresses the current state of US vaccinations and the robust growth in Pfizer's ...
Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...
Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.
Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...
The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...
By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...
Shares of Pfizer Inc. PFE slipped 1.19% to $24.08 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 7,499.36 and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results